AI assistant
BioAge Labs, Inc. — Director's Dealing 2026
Feb 3, 2026
33722_dirs_2026-02-03_7fa00d86-2b44-42ed-a0a9-b37bd9f43502.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BioAge Labs, Inc. (BIOA)
CIK: 0001709941
Period of Report: 2026-02-02
Reporting Person: RUBIN PAUL D (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2026-02-02 | Common Stock | M | 5433 | $4.11 | Acquired | 5433 | Direct |
| 2026-02-02 | Common Stock | M | 2000 | $6.57 | Acquired | 7433 | Direct |
| 2026-02-02 | Common Stock | S | 7433 | $18.7500 | Disposed | 0 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2026-02-02 | Stock Option (Right to Buy) | $4.11 | M | 5433 | Disposed | 2030-06-30 | Common Stock (5433) | Direct |
| 2026-02-02 | Stock Option (Right to Buy) | $6.57 | M | 2000 | Disposed | 2032-05-28 | Common Stock (2000) | Direct |
Footnotes
F1: The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024.
F2: This option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on May 11, 2024.
F3: The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on April 1, 2022, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.